Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
about
Predictive value of BRCA1 expression on the efficacy of chemotherapy based on anti-microtubule agents: a pooled analysis across different malignancies and agentsKilling cancer with platycodin D through multiple mechanismsStabilizing versus destabilizing the microtubules: a double-edge sword for an effective cancer treatment option?Protecting the normal in order to better kill the cancerTargeting of radiolabeled J591 antibody to PSMA-expressing tumors: optimization of imaging and therapy based on non-linear compartmental modelingDesign and characteristics of cytotoxic fibroblast growth factor 1 conjugate for fibroblast growth factor receptor-targeted cancer therapy.The tumor-inhibitory effectiveness of a novel anti-Trop2 Fab conjugate in pancreatic cancer.PPMP, a novel tubulin-depolymerizing agent against esophageal cancer in patient-derived tumor xenografts.CD64-directed microtubule associated protein tau kills leukemic blasts ex vivo.WX-132-18B, a novel microtubule inhibitor, exhibits promising anti-tumor effects.Optimization of Tubulysin Antibody-Drug Conjugates: A Case Study in Addressing ADC Metabolism.Interactome Analysis of Microtubule-targeting Agents Reveals Cytotoxicity Bases in Normal Cells.Human MAP Tau Based Targeted Cytolytic Fusion Proteins.Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.SYD985, a Novel Duocarmycin-Based HER2-Targeting Antibody-Drug Conjugate, Shows Antitumor Activity in Uterine and Ovarian Carcinosarcoma with HER2/Neu Expression.DNA damaging agent-based antibody-drug conjugates for cancer therapy
P2860
Q26748931-693272B1-3FCA-4ACD-970D-D99C45F7E353Q26773408-243C807A-0078-4672-9B1E-C23E29D4E863Q26781365-59D9AF0E-9500-42CA-817E-2A7BCB252394Q26801291-04B50365-761A-471F-9393-390EAC8AEA25Q36491493-41F9ED0A-F7B2-43F8-B48B-C0FFB0BA9A05Q37175328-1CCD188D-93D0-42E2-98A2-98E4279A4EEEQ37269458-722A52B0-0193-4442-90C5-0A0FCCA50E09Q37327639-D8999BDC-D9A6-4F87-80F2-7AE048D8AAB8Q37687139-AB314A74-E33F-4E35-8A29-453E87BF89AEQ42700882-E8CB099D-1D70-481A-83B2-89FADA44A6BAQ46610972-C5F2DBD6-6345-49F9-9682-B224DE527D54Q47288270-9FD485BF-DF1B-46A7-8184-F7D6BA045B2AQ50921086-AF315CEA-29BF-448F-A262-50AB9C341244Q52658297-62768D2E-9BD8-47E8-AD4C-F9D2219C8EBAQ53178110-72A10D2B-16E0-49A6-9A1B-636A7865C05CQ57192403-2864D472-4792-4600-B52D-8E3035C61802
P2860
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
description
2014 nî lūn-bûn
@nan
2014 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@ast
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@en
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@nl
type
label
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@ast
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@en
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@nl
prefLabel
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@ast
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@en
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@nl
P2093
P2860
P356
P1476
Microtubule inhibitor-based antibody-drug conjugates for cancer therapy.
@en
P2093
Daniel P Nguyen
Eleni Nackos
Kelsey Klute
Neil H Bander
Scott T Tagawa
Shinsuke Tasaki
P2860
P304
P356
10.2147/OTT.S46887
P407
P577
2014-12-03T00:00:00Z